Clinical Trial Update: Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS [Phase 2]

View source ↗

Summary

Phase II study evaluating azacitidine with sargramostim as maintenance therapy for poor-risk AML or MDS has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• sargramostim (sargramostim)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-09-02